Bayer’s bridge back to growth

With its two top-selling products facing a loss of exclusivity, Bayer is betting on stronger-than-expected launches and a revamped pipeline to offset revenue declines and return to near-term growth.

Achieving that outcome will require more things to go right than wrong. ...